Biopharmaceutical companies in South Korea are fast-developing biosimilars referencing 'Keytruda (pembrolizumab),' which has ranked no.1 in global sales. Samsung Bioepis and Celltrion have initiated global phase 3 trials.

Due to Keytruda’s leading position in global sales, competition is expected among the companies mentioned above, as well as U.S.-based Amgen and Swiss Sandoz, to develop biosimilars.

Pharmaceutical companies in Korea and overseas are initiating global phase 3 trials for 'Keytruda biosimilar'

According to industry sources on June 17th, Celltrion recently submitted an IND to the U.S. Food and Drug Administration (FDA) for its 'CT-P51,' which is bein